You are here

  • Home
  • Archive
  • Volume 11, Issue Suppl 1
  • 618 Phase 1 clinical trial evaluating the safety, biologic and anti-tumor activity of the novel STING agonist IMSA101 administered both as monotherapy and in combination with PD-(L)1 checkpoint inhibitors

Article metrics

Article menu

Download PDFPDF

Regular and Young Investigator Award Abstracts
Clinical Trial Completed
618 Phase 1 clinical trial evaluating the safety, biologic and anti-tumor activity of the novel STING agonist IMSA101 administered both as monotherapy and in combination with PD-(L)1 checkpoint inhibitors

 

Online download statistics by month:

Online download statistics by month: November 2023 to June 2025

AbstractFullPdf
Nov 2023284032
Dec 202379016
Jan 20248806
Feb 20247608
Mar 2024148023
Apr 2024140011
May 2024126018
Jun 2024110016
Jul 2024146019
Aug 2024130010
Sep 2024116034
Oct 2024158025
Nov 2024182023
Dec 2024128021
Jan 2025156013
Feb 202552029
Mar 20250017
Apr 2025109
May 20250023
Jun 20250014
Total21200367